Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04629703
Recruitment Status : Recruiting
First Posted : November 16, 2020
Last Update Posted : November 30, 2021
Information provided by (Responsible Party):
Rigel Pharmaceuticals